As of Aug 27
| -0.03 / -0.04%|
The 2 analysts offering 12-month price forecasts for KYTHERA Biopharmaceuticals Inc have a median target of 69.50, with a high estimate of 75.00 and a low estimate of 64.00. The median estimate represents a -6.95% decrease from the last price of 74.69.
The current consensus among 2 polled investment analysts is to Buy stock in KYTHERA Biopharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.